NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Cancer Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



B-Cell Lymphoma



Research from H.Y. Dong and co-researchers in the area of B-cell lymphoma published



September 30th, 2008

"The B-cell-specific transcription factor PAX-5 is physiologically expressed in normal B cells and silenced in plasma cells. The aim of this study was to determine whether PAX-5 expression is universal among B-cell malignancies," scientists in the United States report.

"A wide spectrum of B-cell malignancies were subjected to immunohistochemical analysis for PAX-5 expression. The study was especially focused on cases lacking CD20, such as precursor B-cell acute lymphoblastic leukaemia (preB-ALL), CD20- B-cell lymphomas, classical Hodgkin's lymphoma (CHL) and B-cell lymphomas with significant plasmacytic differentiation. Strong PAX-5 expression was identified, without...


Source: Cancer Weekly (2008-09-30)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login